Fig 2: ROC for evaluating the association between plasma Ninj1 and AF

Fig 3: Ninj1 plasma levels in participants with or without AF. A Higher plasma Ninj1 levels in patients with AF than in controls. ***P < 0.001, Student's t-test. B Plasma Ninj1 levels in participants with different types of AF and controls. ***P < 0.001; ns, no significance. Student's t-test

Fig 4: Elevated NINJ1 expression in NEC lesions. (a–c) Representative immunohistochemistry (IHC) images showing NINJ1 protein localization (brown) in neonatal intestinal tissues. Scale bars: 200 μm (a), 100 μm (b), and 20 μm (c). (d, e) Transcriptomic analysis derived from the GSE46619 dataset. (d) Comparison of NINJ1 and NINJ2 abundance levels in neonatal intestinal tissues. (e) Differential expression of NINJ1 in NEC samples compared to controls. (f) Quantification of NINJ1 immunohistochemical staining intensity. Data are presented as mean ± SEM. ***P < 0.001.****p < 0.0001. NEC, necrotizing enterocolitis; NINJ1, nerve injury-induced protein 1; NINJ2, ninjurin 2

Fig 5: Serum levels of NINJ1 in infants with NEC. (a) Comparison of serum NINJ1 levels between infants with NEC (n = 68) and matched controls (n = 42). (b) Comparison of NINJ1 levels among the Control (n = 42), medically managed NEC (n = 40), and surgically treated NEC (n = 28) groups. (c) Comparison of NINJ1 levels among the Control (n = 42), non-perforated NEC (Non-perf NEC; n = 42), and perforated NEC (Perf NEC; n = 26) groups. Serum NINJ1 concentrations were quantified via ELISA. Data are presented as median and interquartile range (IQR). Differences between two groups were analyzed using the Mann-Whitney U test (a), whereas statistical significance among three groups was evaluated using the Kruskal-Wallis H test followed by Dunn’s post hoc test (b, c). ** P < 0.01, ***P < 0.001. Abbreviations: NINJ1, nerve injury-induced protein 1; NEC, necrotizing enterocolitis